Condition Directory

ALS clinical trials

Directory of U.S. ClinicalTrials.gov public records for ALS. Browse ALS recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 21, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

486

Shown on this page

Current sort

How ALS studies are organized in the registry

Listings appear under both the abbreviation ALS and the full name “amyotrophic lateral sclerosis,” and some related records use “motor neuron disease.” The total volume is modest, so browsing the unfiltered list is practical; expanded-access records also appear in this condition and are labeled as such in the study-type field.

Terms that often appear in related listings

amyotrophic lateral sclerosis motor neuron disease SOD1 expanded access

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 49–60 of 486 matching trials for ALS.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Structured Communicative Interaction, Clear Speech, Unstructured communicative interaction, Clear Speech Structured Communicative Interaction; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Amyotrophic Lateral Sclerosis, Gastrointestinal Intolerance, Enteral Nutrition Therapy
Interventions: Medical Food; Other
Lead sponsor: Andrea Charvet; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: nL-TARDB-006; Drug
Lead sponsor: n-Lorem Foundation; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: St Louis, Missouri • New York, New York

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
Interventions: Not listed
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Amyotrophic Lateral Sclerosis, ALS
Interventions: Magnetic Resonance Imaging, Plasma neurofilament light chain (NfL) quantification; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Gainesville, Florida • Evanston, Illinois • Minneapolis, Minnesota

Conditions: ALS (Amyotrophic Lateral Sclerosis)
Interventions: Digoxin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Davie, Florida • Chicago, Illinois • Boston, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: XT-150; Biological
Lead sponsor: Xalud Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 4
States / cities: Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophy
Interventions: Mobile neural decoding platform (mobile iBCI); Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Placebo, Riluzole (100 mg); Drug
Lead sponsor: PhenoNet, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Scottsdale, Arizona • La Jolla, California • San Francisco, California + 2 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: ION363, Placebo; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 8
States / cities: La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

About this ALS clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list ALS as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within ALS.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

ALS clinical trials

How ALS studies are organized in the registry

Filter and sort this condition

Live official records

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis

Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications

Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS

Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS

Digital Speech Markers for Monitoring ALS in Spanish Speakers

Multicenter ALS Imaging Study

Trial of Oral Digoxin in Individuals With Amyotrophic Lateral Sclerosis (ALS)

Safety Study of XT-150 in Participants With ALS

iBCI Optimization for Veterans With Paralysis

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

HEALEY ALS Platform Trial - Master Protocol

About this ALS clinical trials directory page